ReticulohistiocytomaSymptoms, Doctors, Treatments, Advances & More
Learn About Reticulohistiocytoma
- Reticulohistiocytoma
- Solitary histiocytoma
- Solitary reticulohistiocytosis
ETSU Pediatrics- St. Jude's Clinic
Kim Nichols is a Hematologist and an Oncologist practicing medicine in Johnson City, Tennessee. Dr. Nichols is rated as an Elite provider by MediFind in the treatment of Reticulohistiocytoma. She is also highly rated in 11 other conditions, according to our data. Her clinical expertise encompasses Hemophagocytic Lymphohistiocytosis, Non-Langerhans-Cell Histiocytosis, Reticulohistiocytoma, Histiocytosis, and Bone Marrow Transplant. Dr. Nichols is board certified in American Board Of Pediatrics.
The Children's Hospital At Montefiore
Melissa Wasserstein is a Pediatrics provider practicing medicine in Bronx, New York. Dr. Wasserstein is rated as an Elite provider by MediFind in the treatment of Reticulohistiocytoma. She is also highly rated in 7 other conditions, according to our data. Her clinical expertise encompasses Acid Sphingomyelinase Deficiency (ASMD), Niemann-Pick Disease, Reticulohistiocytoma, and Splenomegaly.
Office
Carl Allen is a Hematologist and an Oncologist practicing medicine in Houston, Texas. Dr. Allen is rated as an Elite provider by MediFind in the treatment of Reticulohistiocytoma. He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Langerhans Cell Histiocytosis, Reticulohistiocytoma, Histiocytosis, Hemophagocytic Lymphohistiocytosis, and Bone Marrow Transplant.
Background: Niemann-Pick type C (NPC) disease is a rare, progressive neurodegenerative disease that affects mainly the brain, liver, and spleen but also other parts of the body. There is no cure for NPC, and symptoms only get worse over time. Symptoms can include seizures, difficulty moving or talking, or dementia. But symptoms can vary among different people with the disease. Some may have seizures, while ot...
Summary: BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced/meta...
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center